Naos emerges with strong returns


Adding 2.07% to its year-to-date performance of 26.23%, the Naos Emerging long/short equity fund had a good month, thanks to gains on the long book.

The 130/30 long-biased fund invests in stocks outside the S&P/ASX 100 Index, predominantly in small and micro-caps, and the shorts the index. The highlights of April’s gains include mortgage provider RHG, which paid out a larger than expected dividend as well as Patrys, explains Naos’ Sebastian Evans. The life sciences company is the only one in the world producing natural human antibodies and is in clinical trials for a product to treat melanoma.